Global Treating Chronic Myeloid Leukemia by Phase Market Insights, Forecast to 2030

TABLE OF CONTENTS

1 Report Overview

• 1.1 Study Scope
• 1.2 Market Analysis by Type
  • 1.2.1 Global Treating Chronic Myeloid Leukemia by Phase Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
  • 1.2.2 Chronic Phase
  • 1.2.3 Accelerated Phase
  • 1.2.4 Blast Phase
• 1.3 Market by Application
  • 1.3.1 Global Treating Chronic Myeloid Leukemia by Phase Market Share by Application: 2019 VS 2023 VS 2030
  • 1.3.2 Hospitals
  • 1.3.3 Clinics
  • 1.3.4 Others
• 1.4 Assumptions and Limitations
• 1.5 Study Objectives
• 1.6 Years Considered

2 Global Growth Trends

• 2.1 Global Treating Chronic Myeloid Leukemia by Phase Market Perspective (2019-2030)
• 2.2 Global Treating Chronic Myeloid Leukemia by Phase Growth Trends by Region
  • 2.2.1 Global Treating Chronic Myeloid Leukemia by Phase Market Size by Region: 2019 VS 2023 VS 2030
  • 2.2.2 Treating Chronic Myeloid Leukemia by Phase Historic Market Size by Region (2019-2024)
  • 2.2.3 Treating Chronic Myeloid Leukemia by Phase Forecasted Market Size by Region (2025-2030)
• 2.3 Treating Chronic Myeloid Leukemia by Phase Market Dynamics
  • 2.3.1 Treating Chronic Myeloid Leukemia by Phase Industry Trends
  • 2.3.2 Treating Chronic Myeloid Leukemia by Phase Market Drivers
  • 2.3.3 Treating Chronic Myeloid Leukemia by Phase Market Challenges
  • 2.3.4 Treating Chronic Myeloid Leukemia by Phase Market Restraints

3 Competition Landscape by Key Players

• 3.1 Global Revenue Treating Chronic Myeloid Leukemia by Phase by Players
  • 3.1.1 Global Treating Chronic Myeloid Leukemia by Phase Revenue by Players (2019-2024)
  • 3.1.2 Global Treating Chronic Myeloid Leukemia by Phase Revenue Market Share by Players (2019-2024)
• 3.2 Global Treating Chronic Myeloid Leukemia by Phase Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
• 3.3 Global Key Players of Treating Chronic Myeloid Leukemia by Phase, Ranking by Revenue, 2022 VS 2023 VS 2024
• 3.4 Global Treating Chronic Myeloid Leukemia by Phase Market Concentration Ratio
  • 3.4.1 Global Treating Chronic Myeloid Leukemia by Phase Market Concentration Ratio (CR5 and HHI)
  • 3.4.2 Global Top 10 and Top 5 Companies by Treating Chronic Myeloid Leukemia by Phase Revenue in 2023
• 3.5 Global Key Players of Treating Chronic Myeloid Leukemia by Phase Head office and Area Served
• 3.6 Global Key Players of Treating Chronic Myeloid Leukemia by Phase, Product and Application
• 3.7 Global Key Players of Treating Chronic Myeloid Leukemia by Phase, Date of Enter into This Industry
• 3.8 Mergers & Acquisitions, Expansion Plans

4 Treating Chronic Myeloid Leukemia by Phase Breakdown Data by Type

• 4.1 Global Treating Chronic Myeloid Leukemia by Phase Historic Market Size by Type (2019-2024)
• 4.2 Global Treating Chronic Myeloid Leukemia by Phase Forecasted Market Size by Type (2025-2030)

5 Treating Chronic Myeloid Leukemia by Phase Breakdown Data by Application

• 5.1 Global Treating Chronic Myeloid Leukemia by Phase Historic Market Size by Application (2019-2024)
• 5.2 Global Treating Chronic Myeloid Leukemia by Phase Forecasted Market Size by Application (2025-2030)

6 North America

• 6.1 North America Treating Chronic Myeloid Leukemia by Phase Market Size (2019-2030)
• 6.2 North America Treating Chronic Myeloid Leukemia by Phase Market Size by Type
  • 6.2.1 North America Treating Chronic Myeloid Leukemia by Phase Market Size by Type (2019-2024)
  • 6.2.2 North America Treating Chronic Myeloid Leukemia by Phase Market Size by Type (2025-2030)
  • 6.2.3 North America Treating Chronic Myeloid Leukemia by Phase Market Share by Type (2019-2030)
• 6.3 North America Treating Chronic Myeloid Leukemia by Phase Market Size by Application
  • 6.3.1 North America Treating Chronic Myeloid Leukemia by Phase Market Size by Application (2019-2024)
  • 6.3.2 North America Treating Chronic Myeloid Leukemia by Phase Market Size by Application (2025-2030)
  • 6.3.3 North America Treating Chronic Myeloid Leukemia by Phase Market Share by Application (2019-2030)
• 6.4 North America Treating Chronic Myeloid Leukemia by Phase Market Size by Country
  • 6.4.1 North America Treating Chronic Myeloid Leukemia by Phase Market Size by Country: 2019 VS 2023 VS 2030
  • 6.4.2 North America Treating Chronic Myeloid Leukemia by Phase Market Size by Country (2019-2024)
  • 6.4.3 North America Treating Chronic Myeloid Leukemia by Phase Market Share by Country (2025-2030)
  • 6.4.4 United States
  • 6.4.5 Canada

7 Europe

• 7.1 Europe Treating Chronic Myeloid Leukemia by Phase Market Size (2019-2030)
• 7.2 Europe Treating Chronic Myeloid Leukemia by Phase Market Size by Type
  • 7.2.1 Europe Treating Chronic Myeloid Leukemia by Phase Market Size by Type (2019-2024)
  • 7.2.2 Europe Treating Chronic Myeloid Leukemia by Phase Market Size by Type (2025-2030)
  • 7.2.3 Europe Treating Chronic Myeloid Leukemia by Phase Market Share by Type (2019-2030)
• 7.3 Europe Treating Chronic Myeloid Leukemia by Phase Market Size by Application
  • 7.3.1 Europe Treating Chronic Myeloid Leukemia by Phase Market Size by Application (2019-2024)
  • 7.3.2 Europe Treating Chronic Myeloid Leukemia by Phase Market Size by Application (2025-2030)
  • 7.3.3 Europe Treating Chronic Myeloid Leukemia by Phase Market Share by Application (2019-2030)
• 7.4 Europe Treating Chronic Myeloid Leukemia by Phase Market Size by Country
  • 7.4.1 Europe Treating Chronic Myeloid Leukemia by Phase Market Size by Country: 2019 VS 2023 VS 2030
  • 7.4.2 Europe Treating Chronic Myeloid Leukemia by Phase Market Size by Country (2019-2024)
  • 7.4.3 Europe Treating Chronic Myeloid Leukemia by Phase Market Size by Country (2025-2030)
  • 7.4.4 Germany
  • 7.4.5 France
  • 7.4.6 U.K.
  • 7.4.7 Italy
  • 7.4.8 Russia
  • 7.4.9 Nordic Countries

8 China

• 8.1 China Treating Chronic Myeloid Leukemia by Phase Market Size (2019-2030)
• 8.2 China Treating Chronic Myeloid Leukemia by Phase Market Size by Type
  • 8.2.1 China Treating Chronic Myeloid Leukemia by Phase Market Size by Type (2019-2024)
  • 8.2.2 China Treating Chronic Myeloid Leukemia by Phase Market Size by Type (2025-2030)
  • 8.2.3 China Treating Chronic Myeloid Leukemia by Phase Market Share by Type (2019-2030)
• 8.3 China Treating Chronic Myeloid Leukemia by Phase Market Size by Application
  • 8.3.1 China Treating Chronic Myeloid Leukemia by Phase Market Size by Application (2019-2024)
  • 8.3.2 China Treating Chronic Myeloid Leukemia by Phase Market Size by Application (2025-2030)
  • 8.3.3 China Treating Chronic Myeloid Leukemia by Phase Market Share by Application (2019-2030)

9 Asia (excluding China)

• 9.1 Asia Treating Chronic Myeloid Leukemia by Phase Market Size (2019-2030)
• 9.2 Asia Treating Chronic Myeloid Leukemia by Phase Market Size by Type
  • 9.2.1 Asia Treating Chronic Myeloid Leukemia by Phase Market Size by Type (2019-2024)
  • 9.2.2 Asia Treating Chronic Myeloid Leukemia by Phase Market Size by Type (2025-2030)
  • 9.2.3 Asia Treating Chronic Myeloid Leukemia by Phase Market Share by Type (2019-2030)
• 9.3 Asia Treating Chronic Myeloid Leukemia by Phase Market Size by Application
  • 9.3.1 Asia Treating Chronic Myeloid Leukemia by Phase Market Size by Application (2019-2024)
  • 9.3.2 Asia Treating Chronic Myeloid Leukemia by Phase Market Size by Application (2025-2030)
  • 9.3.3 Asia Treating Chronic Myeloid Leukemia by Phase Market Share by Application (2019-2030)
• 9.4 Asia Treating Chronic Myeloid Leukemia by Phase Market Size by Region
  • 9.4.1 Asia Treating Chronic Myeloid Leukemia by Phase Market Size by Region: 2019 VS 2023 VS 2030
  • 9.4.2 Asia Treating Chronic Myeloid Leukemia by Phase Market Size by Region (2019-2024)
  • 9.4.3 Asia Treating Chronic Myeloid Leukemia by Phase Market Size by Region (2025-2030)
  • 9.4.4 Japan
  • 9.4.5 South Korea
  • 9.4.6 China Taiwan
  • 9.4.7 Southeast Asia
  • 9.4.8 India
  • 9.4.9 Australia

10 Middle East, Africa, and Latin America

• 10.1 Middle East, Africa, and Latin America Treating Chronic Myeloid Leukemia by Phase Market Size (2019-2030)
• 10.2 Middle East, Africa, and Latin America Treating Chronic Myeloid Leukemia by Phase Market Size by Type
  • 10.2.1 Middle East, Africa, and Latin America Treating Chronic Myeloid Leukemia by Phase Market Size by Type (2019-2024)
  • 10.2.2 Middle East, Africa, and Latin America Treating Chronic Myeloid Leukemia by Phase Market Size by Type (2025-2030)
  • 10.2.3 Middle East, Africa, and Latin America Treating Chronic Myeloid Leukemia by Phase Market Share by Type (2019-2030)
• 10.3 Middle East, Africa, and Latin America Treating Chronic Myeloid Leukemia by Phase Market Size by Application
  • 10.3.1 Middle East, Africa, and Latin America Treating Chronic Myeloid Leukemia by Phase Market Size by Application (2019-2024)
  • 10.3.2 Middle East, Africa, and Latin America Treating Chronic Myeloid Leukemia by Phase Market Size by Application (2025-2030)
  • 10.3.3 Middle East, Africa, and Latin America Treating Chronic Myeloid Leukemia by Phase Market Share by Application (2019-2030)
• 10.4 Middle East, Africa, and Latin America Treating Chronic Myeloid Leukemia by Phase Market Size by Country
  • 10.4.1 Middle East, Africa, and Latin America Treating Chronic Myeloid Leukemia by Phase Market Size by Country: 2019 VS 2023 VS 2030
  • 10.4.2 Middle East, Africa, and Latin America Treating Chronic Myeloid Leukemia by Phase Market Size by Country (2019-2024)
  • 10.4.3 Middle East, Africa, and Latin America Treating Chronic Myeloid Leukemia by Phase Market Size by Country (2025-2030)
  • 10.4.4 Brazil
  • 10.4.5 Mexico
  • 10.4.6 Turkey
  • 10.4.7 Saudi Arabia
  • 10.4.8 Israel
  • 10.4.9 GCC Countries

11 Key Players Profiles

• 11.1 Novartis
  • 11.1.1 Novartis Company Details
  • 11.1.2 Novartis Business Overview
  • 11.1.3 Novartis Treating Chronic Myeloid Leukemia by Phase Introduction
  • 11.1.4 Novartis Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)
  • 11.1.5 Novartis Recent Development
• 11.2 Bristol Myers Squibb
  • 11.2.1 Bristol Myers Squibb Company Details
  • 11.2.2 Bristol Myers Squibb Business Overview
  • 11.2.3 Bristol Myers Squibb Treating Chronic Myeloid Leukemia by Phase Introduction
  • 11.2.4 Bristol Myers Squibb Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)
  • 11.2.5 Bristol Myers Squibb Recent Development
• 11.3 Pfizer
  • 11.3.1 Pfizer Company Details
  • 11.3.2 Pfizer Business Overview
  • 11.3.3 Pfizer Treating Chronic Myeloid Leukemia by Phase Introduction
  • 11.3.4 Pfizer Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)
  • 11.3.5 Pfizer Recent Development
• 11.4 Hansoh Pharmaceutical
  • 11.4.1 Hansoh Pharmaceutical Company Details
  • 11.4.2 Hansoh Pharmaceutical Business Overview
  • 11.4.3 Hansoh Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Introduction
  • 11.4.4 Hansoh Pharmaceutical Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)
  • 11.4.5 Hansoh Pharmaceutical Recent Development
• 11.5 Takeda Pharmaceuticals
  • 11.5.1 Takeda Pharmaceuticals Company Details
  • 11.5.2 Takeda Pharmaceuticals Business Overview
  • 11.5.3 Takeda Pharmaceuticals Treating Chronic Myeloid Leukemia by Phase Introduction
  • 11.5.4 Takeda Pharmaceuticals Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)
  • 11.5.5 Takeda Pharmaceuticals Recent Development
• 11.6 Sun Pharmaceuticals
  • 11.6.1 Sun Pharmaceuticals Company Details
  • 11.6.2 Sun Pharmaceuticals Business Overview
  • 11.6.3 Sun Pharmaceuticals Treating Chronic Myeloid Leukemia by Phase Introduction
  • 11.6.4 Sun Pharmaceuticals Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)
  • 11.6.5 Sun Pharmaceuticals Recent Development
• 11.7 Mylan
  • 11.7.1 Mylan Company Details
  • 11.7.2 Mylan Business Overview
  • 11.7.3 Mylan Treating Chronic Myeloid Leukemia by Phase Introduction
  • 11.7.4 Mylan Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)
  • 11.7.5 Mylan Recent Development
• 11.8 Dr. Reddy's Laboratories
  • 11.8.1 Dr. Reddy's Laboratories Company Details
  • 11.8.2 Dr. Reddy's Laboratories Business Overview
  • 11.8.3 Dr. Reddy's Laboratories Treating Chronic Myeloid Leukemia by Phase Introduction
  • 11.8.4 Dr. Reddy's Laboratories Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)
  • 11.8.5 Dr. Reddy's Laboratories Recent Development
• 11.9 Teva
  • 11.9.1 Teva Company Details
  • 11.9.2 Teva Business Overview
  • 11.9.3 Teva Treating Chronic Myeloid Leukemia by Phase Introduction
  • 11.9.4 Teva Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)
  • 11.9.5 Teva Recent Development
• 11.10 Eugia Pharma
  • 11.10.1 Eugia Pharma Company Details
  • 11.10.2 Eugia Pharma Business Overview
  • 11.10.3 Eugia Pharma Treating Chronic Myeloid Leukemia by Phase Introduction
  • 11.10.4 Eugia Pharma Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)
  • 11.10.5 Eugia Pharma Recent Development
• 11.11 Hetero
  • 11.11.1 Hetero Company Details
  • 11.11.2 Hetero Business Overview
  • 11.11.3 Hetero Treating Chronic Myeloid Leukemia by Phase Introduction
  • 11.11.4 Hetero Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)
  • 11.11.5 Hetero Recent Development
• 11.12 Sawai Pharmaceutical
  • 11.12.1 Sawai Pharmaceutical Company Details
  • 11.12.2 Sawai Pharmaceutical Business Overview
  • 11.12.3 Sawai Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Introduction
  • 11.12.4 Sawai Pharmaceutical Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)
  • 11.12.5 Sawai Pharmaceutical Recent Development
• 11.13 Lupin
  • 11.13.1 Lupin Company Details
  • 11.13.2 Lupin Business Overview
  • 11.13.3 Lupin Treating Chronic Myeloid Leukemia by Phase Introduction
  • 11.13.4 Lupin Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)
  • 11.13.5 Lupin Recent Development
• 11.14 Apotex
  • 11.14.1 Apotex Company Details
  • 11.14.2 Apotex Business Overview
  • 11.14.3 Apotex Treating Chronic Myeloid Leukemia by Phase Introduction
  • 11.14.4 Apotex Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)
  • 11.14.5 Apotex Recent Development
• 11.15 Chia Tai Tianqing Pharmaceutical
  • 11.15.1 Chia Tai Tianqing Pharmaceutical Company Details
  • 11.15.2 Chia Tai Tianqing Pharmaceutical Business Overview
  • 11.15.3 Chia Tai Tianqing Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Introduction
  • 11.15.4 Chia Tai Tianqing Pharmaceutical Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)
  • 11.15.5 Chia Tai Tianqing Pharmaceutical Recent Development
• 11.16 Qilu Pharmaceutical
  • 11.16.1 Qilu Pharmaceutical Company Details
  • 11.16.2 Qilu Pharmaceutical Business Overview
  • 11.16.3 Qilu Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Introduction
  • 11.16.4 Qilu Pharmaceutical Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)
  • 11.16.5 Qilu Pharmaceutical Recent Development
• 11.17 CSPC Ouyi Pharmaceutical
  • 11.17.1 CSPC Ouyi Pharmaceutical Company Details
  • 11.17.2 CSPC Ouyi Pharmaceutical Business Overview
  • 11.17.3 CSPC Ouyi Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Introduction
  • 11.17.4 CSPC Ouyi Pharmaceutical Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)
  • 11.17.5 CSPC Ouyi Pharmaceutical Recent Development
• 11.18 Suzhou Thery Pharmaceutical
  • 11.18.1 Suzhou Thery Pharmaceutical Company Details
  • 11.18.2 Suzhou Thery Pharmaceutical Business Overview
  • 11.18.3 Suzhou Thery Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Introduction
  • 11.18.4 Suzhou Thery Pharmaceutical Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)
  • 11.18.5 Suzhou Thery Pharmaceutical Recent Development
• 11.19 Lunan Pharmaceutical
  • 11.19.1 Lunan Pharmaceutical Company Details
  • 11.19.2 Lunan Pharmaceutical Business Overview
  • 11.19.3 Lunan Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Introduction
  • 11.19.4 Lunan Pharmaceutical Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)
  • 11.19.5 Lunan Pharmaceutical Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

• 13.1 Research Methodology
  • 13.1.1 Methodology/Research Approach
    • 13.1.1.1 Research Programs/Design
    • 13.1.1.2 Market Size Estimation
    • 13.1.1.3 Market Breakdown and Data Triangulation
  • 13.1.2 Data Source
    • 13.1.2.1 Secondary Sources
    • 13.1.2.2 Primary Sources
• 13.2 Author Details
• 13.3 Disclaimer

List of Tables

Table 1. Global Treating Chronic Myeloid Leukemia by Phase Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030

Table 2. Key Players of Chronic Phase

Table 3. Key Players of Accelerated Phase

Table 4. Key Players of Blast Phase

Table 5. Global Treating Chronic Myeloid Leukemia by Phase Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030

Table 6. Global Treating Chronic Myeloid Leukemia by Phase Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030

Table 7. Global Treating Chronic Myeloid Leukemia by Phase Market Size by Region (2019-2024) & (US$ Million)

Table 8. Global Treating Chronic Myeloid Leukemia by Phase Market Share by Region (2019-2024)

Table 9. Global Treating Chronic Myeloid Leukemia by Phase Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 10. Global Treating Chronic Myeloid Leukemia by Phase Market Share by Region (2025-2030)

Table 11. Treating Chronic Myeloid Leukemia by Phase Market Trends

Table 12. Treating Chronic Myeloid Leukemia by Phase Market Drivers

Table 13. Treating Chronic Myeloid Leukemia by Phase Market Challenges

Table 14. Treating Chronic Myeloid Leukemia by Phase Market Restraints

Table 15. Global Treating Chronic Myeloid Leukemia by Phase Revenue by Players (2019-2024) & (US$ Million)

Table 16. Global Treating Chronic Myeloid Leukemia by Phase Market Share by Players (2019-2024)

Table 17. Global Top Treating Chronic Myeloid Leukemia by Phase Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Treating Chronic Myeloid Leukemia by Phase as of 2023)

Table 18. Global Treating Chronic Myeloid Leukemia by Phase Industry Ranking 2022 VS 2023

Table 19. Global 5 Largest Players Market Share by Treating Chronic Myeloid Leukemia by Phase Revenue (CR5 and HHI) & (2019-2024)

Table 20. Global Key Players of Treating Chronic Myeloid Leukemia by Phase, Headquarters and Area Served

Table 21. Global Key Players of Treating Chronic Myeloid Leukemia by Phase, Product and Application

Table 22. Global Key Players of Treating Chronic Myeloid Leukemia by Phase, Date of Enter into This Industry

Table 23. Mergers & Acquisitions, Expansion Plans

Table 24. Global Treating Chronic Myeloid Leukemia by Phase Market Size by Type (2019-2024) & (US$ Million)

Table 25. Global Treating Chronic Myeloid Leukemia by Phase Revenue Market Share by Type (2019-2024)

Table 26. Global Treating Chronic Myeloid Leukemia by Phase Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 27. Global Treating Chronic Myeloid Leukemia by Phase Revenue Market Share by Type (2025-2030)

Table 28. Global Treating Chronic Myeloid Leukemia by Phase Market Size by Application (2019-2024) & (US$ Million)

Table 29. Global Treating Chronic Myeloid Leukemia by Phase Revenue Market Share by Application (2019-2024)

Table 30. Global Treating Chronic Myeloid Leukemia by Phase Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 31. Global Treating Chronic Myeloid Leukemia by Phase Revenue Market Share by Application (2025-2030)

Table 32. North America Treating Chronic Myeloid Leukemia by Phase Market Size by Type (2019-2024) & (US$ Million)

Table 33. North America Treating Chronic Myeloid Leukemia by Phase Market Size by Type (2025-2030) & (US$ Million)

Table 34. North America Treating Chronic Myeloid Leukemia by Phase Market Size by Application (2019-2024) & (US$ Million)

Table 35. North America Treating Chronic Myeloid Leukemia by Phase Market Size by Application (2025-2030) & (US$ Million)

Table 36. North America Treating Chronic Myeloid Leukemia by Phase Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030

Table 37. North America Treating Chronic Myeloid Leukemia by Phase Market Size by Country (2019-2024) & (US$ Million)

Table 38. North America Treating Chronic Myeloid Leukemia by Phase Market Size by Country (2025-2030) & (US$ Million)

Table 39. Europe Treating Chronic Myeloid Leukemia by Phase Market Size by Type (2019-2024) & (US$ Million)

Table 40. Europe Treating Chronic Myeloid Leukemia by Phase Market Size by Type (2025-2030) & (US$ Million)

Table 41. Europe Treating Chronic Myeloid Leukemia by Phase Market Size by Application (2019-2024) & (US$ Million)

Table 42. Europe Treating Chronic Myeloid Leukemia by Phase Market Size by Application (2025-2030) & (US$ Million)

Table 43. Europe Treating Chronic Myeloid Leukemia by Phase Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030

Table 44. Europe Treating Chronic Myeloid Leukemia by Phase Market Size by Country (2019-2024) & (US$ Million)

Table 45. Europe Treating Chronic Myeloid Leukemia by Phase Market Size by Country (2025-2030) & (US$ Million)

Table 46. China Treating Chronic Myeloid Leukemia by Phase Market Size by Type (2019-2024) & (US$ Million)

Table 47. China Treating Chronic Myeloid Leukemia by Phase Market Size by Type (2025-2030) & (US$ Million)

Table 48. China Treating Chronic Myeloid Leukemia by Phase Market Size by Application (2019-2024) & (US$ Million)

Table 49. China Treating Chronic Myeloid Leukemia by Phase Market Size by Application (2025-2030) & (US$ Million)

Table 50. Asia Treating Chronic Myeloid Leukemia by Phase Market Size by Type (2019-2024) & (US$ Million)

Table 51. Asia Treating Chronic Myeloid Leukemia by Phase Market Size by Type (2025-2030) & (US$ Million)

Table 52. Asia Treating Chronic Myeloid Leukemia by Phase Market Size by Application (2019-2024) & (US$ Million)

Table 53. Asia Treating Chronic Myeloid Leukemia by Phase Market Size by Application (2025-2030) & (US$ Million)

Table 54. Asia Treating Chronic Myeloid Leukemia by Phase Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030

Table 55. Asia Treating Chronic Myeloid Leukemia by Phase Market Size by Region (2019-2024) & (US$ Million)

Table 56. Asia Treating Chronic Myeloid Leukemia by Phase Market Size by Region (2025-2030) & (US$ Million)

Table 57. Middle East, Africa, and Latin America Treating Chronic Myeloid Leukemia by Phase Market Size by Type (2019-2024) & (US$ Million)

Table 58. Middle East, Africa, and Latin America Treating Chronic Myeloid Leukemia by Phase Market Size by Type (2025-2030) & (US$ Million)

Table 59. Middle East, Africa, and Latin America Treating Chronic Myeloid Leukemia by Phase Market Size by Application (2019-2024) & (US$ Million)

Table 60. Middle East, Africa, and Latin America Treating Chronic Myeloid Leukemia by Phase Market Size by Application (2025-2030) & (US$ Million)

Table 61. Middle East, Africa, and Latin America Treating Chronic Myeloid Leukemia by Phase Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030

Table 62. Middle East, Africa, and Latin America Treating Chronic Myeloid Leukemia by Phase Market Size by Country (2019-2024) & (US$ Million)

Table 63. Middle East, Africa, and Latin America Treating Chronic Myeloid Leukemia by Phase Market Size by Country (2025-2030) & (US$ Million)

Table 64. Novartis Company Details

Table 65. Novartis Business Overview

Table 66. Novartis Treating Chronic Myeloid Leukemia by Phase Product

Table 67. Novartis Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024) & (US$ Million)

Table 68. Novartis Recent Development

Table 69. Bristol Myers Squibb Company Details

Table 70. Bristol Myers Squibb Business Overview

Table 71. Bristol Myers Squibb Treating Chronic Myeloid Leukemia by Phase Product

Table 72. Bristol Myers Squibb Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024) & (US$ Million)

Table 73. Bristol Myers Squibb Recent Development

Table 74. Pfizer Company Details

Table 75. Pfizer Business Overview

Table 76. Pfizer Treating Chronic Myeloid Leukemia by Phase Product

Table 77. Pfizer Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024) & (US$ Million)

Table 78. Pfizer Recent Development

Table 79. Hansoh Pharmaceutical Company Details

Table 80. Hansoh Pharmaceutical Business Overview

Table 81. Hansoh Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Product

Table 82. Hansoh Pharmaceutical Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024) & (US$ Million)

Table 83. Hansoh Pharmaceutical Recent Development

Table 84. Takeda Pharmaceuticals Company Details

Table 85. Takeda Pharmaceuticals Business Overview

Table 86. Takeda Pharmaceuticals Treating Chronic Myeloid Leukemia by Phase Product

Table 87. Takeda Pharmaceuticals Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024) & (US$ Million)

Table 88. Takeda Pharmaceuticals Recent Development

Table 89. Sun Pharmaceuticals Company Details

Table 90. Sun Pharmaceuticals Business Overview

Table 91. Sun Pharmaceuticals Treating Chronic Myeloid Leukemia by Phase Product

Table 92. Sun Pharmaceuticals Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024) & (US$ Million)

Table 93. Sun Pharmaceuticals Recent Development

Table 94. Mylan Company Details

Table 95. Mylan Business Overview

Table 96. Mylan Treating Chronic Myeloid Leukemia by Phase Product

Table 97. Mylan Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024) & (US$ Million)

Table 98. Mylan Recent Development

Table 99. Dr. Reddy's Laboratories Company Details

Table 100. Dr. Reddy's Laboratories Business Overview

Table 101. Dr. Reddy's Laboratories Treating Chronic Myeloid Leukemia by Phase Product

Table 102. Dr. Reddy's Laboratories Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024) & (US$ Million)

Table 103. Dr. Reddy's Laboratories Recent Development

Table 104. Teva Company Details

Table 105. Teva Business Overview

Table 106. Teva Treating Chronic Myeloid Leukemia by Phase Product

Table 107. Teva Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024) & (US$ Million)

Table 108. Teva Recent Development

Table 109. Eugia Pharma Company Details

Table 110. Eugia Pharma Business Overview

Table 111. Eugia Pharma Treating Chronic Myeloid Leukemia by Phase Product

Table 112. Eugia Pharma Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024) & (US$ Million)

Table 113. Eugia Pharma Recent Development

Table 114. Hetero Company Details

Table 115. Hetero Business Overview

Table 116. Hetero Treating Chronic Myeloid Leukemia by Phase Product

Table 117. Hetero Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024) & (US$ Million)

Table 118. Hetero Recent Development

Table 119. Sawai Pharmaceutical Company Details

Table 120. Sawai Pharmaceutical Business Overview

Table 121. Sawai Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Product

Table 122. Sawai Pharmaceutical Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024) & (US$ Million)

Table 123. Sawai Pharmaceutical Recent Development

Table 124. Lupin Company Details

Table 125. Lupin Business Overview

Table 126. Lupin Treating Chronic Myeloid Leukemia by Phase Product

Table 127. Lupin Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024) & (US$ Million)

Table 128. Lupin Recent Development

Table 129. Apotex Company Details

Table 130. Apotex Business Overview

Table 131. Apotex Treating Chronic Myeloid Leukemia by Phase Product

Table 132. Apotex Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024) & (US$ Million)

Table 133. Apotex Recent Development

Table 134. Chia Tai Tianqing Pharmaceutical Company Details

Table 135. Chia Tai Tianqing Pharmaceutical Business Overview

Table 136. Chia Tai Tianqing Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Product

Table 137. Chia Tai Tianqing Pharmaceutical Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024) & (US$ Million)

Table 138. Chia Tai Tianqing Pharmaceutical Recent Development

Table 139. Qilu Pharmaceutical Company Details

Table 140. Qilu Pharmaceutical Business Overview

Table 141. Qilu Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Product

Table 142. Qilu Pharmaceutical Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024) & (US$ Million)

Table 143. Qilu Pharmaceutical Recent Development

Table 144. CSPC Ouyi Pharmaceutical Company Details

Table 145. CSPC Ouyi Pharmaceutical Business Overview

Table 146. CSPC Ouyi Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Product

Table 147. CSPC Ouyi Pharmaceutical Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024) & (US$ Million)

Table 148. CSPC Ouyi Pharmaceutical Recent Development

Table 149. Suzhou Thery Pharmaceutical Company Details

Table 150. Suzhou Thery Pharmaceutical Business Overview

Table 151. Suzhou Thery Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Product

Table 152. Suzhou Thery Pharmaceutical Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024) & (US$ Million)

Table 153. Suzhou Thery Pharmaceutical Recent Development

Table 154. Lunan Pharmaceutical Company Details

Table 155. Lunan Pharmaceutical Business Overview

Table 156. Lunan Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Product

Table 157. Lunan Pharmaceutical Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024) & (US$ Million)

Table 158. Lunan Pharmaceutical Recent Development

Table 159. Research Programs/Design for This Report

Table 160. Key Data Information from Secondary Sources

Table 161. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Treating Chronic Myeloid Leukemia by Phase Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)

Figure 2. Global Treating Chronic Myeloid Leukemia by Phase Market Share by Type: 2023 VS 2030

Figure 3. Chronic Phase Features

Figure 4. Accelerated Phase Features

Figure 5. Blast Phase Features

Figure 6. Global Treating Chronic Myeloid Leukemia by Phase Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)

Figure 7. Global Treating Chronic Myeloid Leukemia by Phase Market Share by Application: 2023 VS 2030

Figure 8. Hospitals Case Studies

Figure 9. Clinics Case Studies

Figure 10. Others Case Studies

Figure 11. Treating Chronic Myeloid Leukemia by Phase Report Years Considered

Figure 12. Global Treating Chronic Myeloid Leukemia by Phase Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 13. Global Treating Chronic Myeloid Leukemia by Phase Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 14. Global Treating Chronic Myeloid Leukemia by Phase Market Share by Region: 2023 VS 2030

Figure 15. Global Treating Chronic Myeloid Leukemia by Phase Market Share by Players in 2023

Figure 16. Global Top Treating Chronic Myeloid Leukemia by Phase Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Treating Chronic Myeloid Leukemia by Phase as of 2023)

Figure 17. The Top 10 and 5 Players Market Share by Treating Chronic Myeloid Leukemia by Phase Revenue in 2023

Figure 18. North America Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 19. North America Treating Chronic Myeloid Leukemia by Phase Market Share by Type (2019-2030)

Figure 20. North America Treating Chronic Myeloid Leukemia by Phase Market Share by Application (2019-2030)

Figure 21. North America Treating Chronic Myeloid Leukemia by Phase Market Share by Country (2019-2030)

Figure 22. United States Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 23. Canada Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 24. Europe Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 25. Europe Treating Chronic Myeloid Leukemia by Phase Market Share by Type (2019-2030)

Figure 26. Europe Treating Chronic Myeloid Leukemia by Phase Market Share by Application (2019-2030)

Figure 27. Europe Treating Chronic Myeloid Leukemia by Phase Market Share by Country (2019-2030)

Figure 28. Germany Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 29. France Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 30. U.K. Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 31. Italy Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 32. Russia Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 33. Nordic Countries Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 34. China Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 35. China Treating Chronic Myeloid Leukemia by Phase Market Share by Type (2019-2030)

Figure 36. China Treating Chronic Myeloid Leukemia by Phase Market Share by Application (2019-2030)

Figure 37. Asia Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 38. Asia Treating Chronic Myeloid Leukemia by Phase Market Share by Type (2019-2030)

Figure 39. Asia Treating Chronic Myeloid Leukemia by Phase Market Share by Application (2019-2030)

Figure 40. Asia Treating Chronic Myeloid Leukemia by Phase Market Share by Region (2019-2030)

Figure 41. Japan Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 42. South Korea Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 43. China Taiwan Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 44. Southeast Asia Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 45. India Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 46. Australia Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 47. Middle East, Africa, and Latin America Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 48. Middle East, Africa, and Latin America Treating Chronic Myeloid Leukemia by Phase Market Share by Type (2019-2030)

Figure 49. Middle East, Africa, and Latin America Treating Chronic Myeloid Leukemia by Phase Market Share by Application (2019-2030)

Figure 50. Middle East, Africa, and Latin America Treating Chronic Myeloid Leukemia by Phase Market Share by Country (2019-2030)

Figure 51. Brazil Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 52. Mexico Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 53. Turkey Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 54. Saudi Arabia Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 55. Israel Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 56. GCC Countries Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 57. Novartis Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)

Figure 58. Bristol Myers Squibb Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)

Figure 59. Pfizer Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)

Figure 60. Hansoh Pharmaceutical Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)

Figure 61. Takeda Pharmaceuticals Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)

Figure 62. Sun Pharmaceuticals Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)

Figure 63. Mylan Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)

Figure 64. Dr. Reddy's Laboratories Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)

Figure 65. Teva Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)

Figure 66. Eugia Pharma Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)

Figure 67. Hetero Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)

Figure 68. Sawai Pharmaceutical Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)

Figure 69. Lupin Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)

Figure 70. Apotex Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)

Figure 71. Chia Tai Tianqing Pharmaceutical Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)

Figure 72. Qilu Pharmaceutical Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)

Figure 73. CSPC Ouyi Pharmaceutical Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)

Figure 74. Suzhou Thery Pharmaceutical Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)

Figure 75. Lunan Pharmaceutical Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)

Figure 76. Bottom-up and Top-down Approaches for This Report

Figure 77. Data Triangulation

Figure 78. Key Executives Interviewed